4DMT Q2 net loss $72.9M; 4D-150 Phase 3 enrollment complete, $200M credit facility

4D Molecular Therapeutics, Inc.

Net loss $72.9M vs $54.7M; R&D expenses $68.3M vs $48.0M; G&A $12.5M vs $11.5M.
Cash $430.6M at June 30, 2026, down from $514.0M; funds into H2 2028.
4D-150 4FRONT-1 topline Q2 2027 (N=523); 4FRONT-2 enrollment complete, topline H2 2027.
PRISM 2-yr data: 78% treatment burden reduction overall, 87% in recently diagnosed; no new inflammation.
$200M Hercules credit facility, initial draw $20M; DME Phase 3 to start Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.